Who We Are
Access Bio is dedicated to advancing global health through innovative in vitro diagnostic technologies, delivering high-quality solutions to combat malaria and other infectious diseases. Driven by our commitment to life and health, we continue to lead the way in developing next-generation diagnostics that inspire hope for a healthier world.
U.S. Research & Development
Advancing Innovative in Vitro Diagnostic Technologies
U.S. Manufacturing
Ensuring High-Quality, Reliable Production
Global Distribution
Delivering Diagnostic Solutions Worldwide
Global Health Impact
Expanding Access to Diagnostics
Our Journey
Where we are now
2002
Established and Selected as an "Emerging Bioscience Company" by the New Jersey Economic Development Authority (NJEDA)
2003
Awarded an R&D grant From U.S. Department of Defense
2009
Expanded Global Sales of Malaria Rapid Diagnostic Test (RDT)
2011
Commercialized the World's First G6PD Point-of-Care Testing (POCT)
2013
Ranked #1 in the Global Malaria RDT Market
Listed on the Korea Securities Dealers Automated Quotations (KOSDAQ)
2015-2016
Awarded an R&D grant to Improve the Sensitivity of RDT from the Bill & Melinda Gates Foundation
2020-2022
Ranked #1 in COVID-19 test convenience survey by ECRI (U.S.)
Successfully launched 5 types of COVID-19 Diagnostic Series
2023
Awarded an R&D grant from RAD×®, organized by U.S. National Institute of Health (NIH)
Granted the U.S. patent for CareSuperb™ Technology
2024
Recognized by Life Science Review as the In Vitro Diagnostics Technology Company of the Year 2024
2025
Distributed Over 300 Million COVID-19 Tests in the U.S.
Received FDA 510(k) Clearance for a CareSuperb™-based Antigen Home Test
